{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:22:04Z","timestamp":1770063724016,"version":"3.49.0"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.2169\/internalmedicine.9107-21","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T22:08:27Z","timestamp":1643666907000},"page":"2245-2246","source":"Crossref","is-referenced-by-count":1,"title":["Dasatinib-induced Pulmonary Hypertension"],"prefix":"10.2169","volume":"61","author":[{"given":"Yudai","family":"Tamura","sequence":"first","affiliation":[{"name":"Cardiovascular Center, International University of Health and Welfare Mita Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53: 1801913, 2019.","DOI":"10.1183\/13993003.01913-2018"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Quilot FM, Georges M, Favrolt N, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J 47: 676-679, 2016.","DOI":"10.1183\/13993003.01110-2015"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Riou M, Seferian A, Savale L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J 48: 1517-1519, 2016.","DOI":"10.1183\/13993003.01410-2016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hickey PM, Thompson AA, Charalampopoulos A, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir 48: 1514-1516, 2016.","DOI":"10.1183\/13993003.01004-2016"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90: 1060-1064, 2015.","DOI":"10.1002\/ajh.24174"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127: 1128-1138, 2013.","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 126: 3207-3218, 2016.","DOI":"10.1172\/JCI86249"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 50: 1700217, 2017.","DOI":"10.1183\/13993003.00217-2017"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Montani D, Bergot E, G\u00fcnther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125: 2128-2137, 2012.","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 91: 869-74, 2016.","DOI":"10.1002\/ajh.24423"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fox LC, Cummins KD, Costello B, et al. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv 1: 802-811, 2017.","DOI":"10.1182\/bloodadvances.2016003889"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kubota K, Imai Y, Oh I, Ueno S, Kanda Y, Kario K. Relationship between dasatinib-induced pulmonary hypertension and drug dose. Intern Med 61: 2263-2271, 2022.","DOI":"10.2169\/internalmedicine.8392-21"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/15\/61_9107-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T03:15:30Z","timestamp":1659755730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/15\/61_9107-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":12,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9107-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"article-number":"9107-21"}}